KLYP956 is a non-imidazole-based orally active inhibitor of nitric-oxide synthase dimerization

Molecular Pharmacology

Volumn 76, Issue 1, 2009, Pages 153-162

  Symons, Kent T ^a   Massari, Mark E ^a   Nguyen, Phan M ^a   Lee, Tom T ^a   Roppe, Jeffrey ^a   Bonnefous, Céline ^a   Payne, Joseph E ^a   Smith, Nicholas D ^a   Noble, Stewart A ^a   Sablad, Marciano ^a   Rozenkrants, Natasha ^a   Zhang, Yan ^a   Rao, Tadimeti S ^a   Shiau, Andrew K ^a   Hassig, Christian A ^a,b  

^a Kalypsys Inc   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DIMER; FORMALDEHYDE; HEME; INDUCIBLE NITRIC OXIDE SYNTHASE; KLYP 956; N (3 CHLOROPHENYL) N [(8 FLUORO 2 OXO 1,2 DIHYDROQUINOLIN 4 YL)METHYL] 4 METHYLTHIAZOLE 5 CARBOXAMIDE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; OXYGENASE; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIMERIZATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; EMBRYO; ENDOTOXEMIA; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NOCICEPTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PAIN; PRIORITY JOURNAL; PROTEIN DOMAIN;

ADMINISTRATION, ORAL; ANIMALS; CELLS, CULTURED; DIMERIZATION; ENZYME INHIBITORS; FLUOROQUINOLONES; HUMANS; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; PAIN; SPECIES SPECIFICITY; THIAZOLES;

EID: 67649884447     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.055434     Document Type: Article

References (32)

1. Albengres E, Le Louët H, and Tillement JP (1998) Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 18:83-97. (Pubitemid 28080742)
2. Blasko E, Glaser CB, Devlin JJ, Xia W, Feldman RI, Polokoff MA, Phillips GB, Whitlow M, Auld DS, McMillan K, et al. (2002) Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J Biol Chem 277:295-302. (Pubitemid 34952058)
3. Chida N, Hirasawa Y, Ohkawa T, Ishii Y, Sudo Y, Tamura K, and Mutoh S (2005) Pharmacological profile of FR260330, a novel orally active inducible nitric oxide synthase inhibitor. Eur J Pharmacol 509:71-76. (Pubitemid 40248787)
4. Davey DD, Adler M, Arnaiz D, Eagen K, Erickson S, Guilford W, Kenrick M, Morrissey MM, Ohlmeyer M, Pan G, et al. (2007) Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors. J Med Chem 50:1146-1157. (Pubitemid 46496315)
5. Dubuisson D and Dennis SG (1977) The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4:161-174. (Pubitemid 8234766)
6. Edwards RM, Stack EJ, and Trizna W (1998) Interaction of L-arginine analogs with L-arginine uptake in rat renal brush border membrane vesicles. J Pharmacol Exp Ther 285:1019-1022. (Pubitemid 28277899)
7. G-methylarginine requires NADPH-dependent hydroxylation. J Med Chem 36:491-496.
8. Garcin ED, Arvai AS, Rosenfeld RJ, Kroeger MD, Crane BR, Andersson G, Andrews G, Hamley PJ, Mallinder PR, Nicholls DJ, et al. (2008) Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol 4:700-707.
9. Ghosh S, Wolan D, Adak S, Crane BR, Kwon NS, Tainer JA, Getzoff ED, and Stuehr DJ (1999) Mutational analysis of the tetrahydrobiopterin-binding site in inducible nitric-oxide synthase. J Biol Chem 274:24100-24112. (Pubitemid 129528455)
10. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
11. Jackson SA, Sahni S, Lee L, Luo Y, Nieduzak TR, Liang G, Chiang Y, Collar N, Fink D, He W, et al. (2005) Design, synthesis and characterization of a novel class of coumarin-based inhibitors of inducible nitric oxide synthase. Bioorg Med Chem 13:2723-2739. (Pubitemid 40387483)
12. Kato H, Negoro M, and Wakabayashi I (2005) Effects of acute ethanol administration on LPS-induced expression of cyclooxygenase-2 and inducible nitric oxide synthase in rat alveolar macrophages. Alcohol Clin Exp Res 29:285S-293S. (Pubitemid 43053685)
13. Kolodziejski PJ, Koo JS, and Eissa NT (2004) Regulation of inducible nitric oxide synthase by rapid cellular turnover and cotranslational down-regulation by dimerization inhibitors. Proc Natl Acad Sci U S A 101:18141-18146. (Pubitemid 40054087)
14. Kone BC, Kuncewicz T, Zhang W, and Yu ZY (2003) Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am J Physiol Renal Physiol 285:F178-F190. (Pubitemid 36871190)
15. LaBuda CJ, Koblish M, Tuthill P, Dolle RE, and Little PJ (2006) Antinociceptive activity of the selective INOS inhibitor AR-C102222 in rodent models of inflammatory, neuropathic and post-operative pain. Eur J Pain 10:505-512. (Pubitemid 43947639)
16. Li D, Hayden EY, Panda K, Stuehr DJ, Deng H, Rousseau DL, and Yeh SR (2006) Regulation of the monomer-dimer equilibrium in inducible nitric-oxide synthase by nitric oxide. J Biol Chem 281:8197-8204. (Pubitemid 43847440)
17. McMillan K, Adler M, Auld DS, Baldwin JJ, Blasko E, Browne LJ, Chelsky D, Davey D, Dolle RE, Eagen KA, et al. (2000) Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc Natl Acad Sci U S A 97:1506-1511. (Pubitemid 30118471)
18. McMillan K and Masters BS (1993) Optical difference spectrophotometry as a probe of rat brain nitric oxide synthase heme-substrate interaction. Biochemistry 32: 9875-9880. (Pubitemid 23312411)
19. Naureckiene S, Edris W, Ajit SK, Katz AH, Sreekumar K, Rogers KE, Kennedy JD, and Jones PG (2007) Use of a murine cell line for identification of human nitric oxide synthase inhibitors. J Pharmacol Toxicol Methods 55:303-313. (Pubitemid 46436515)
20. Ohtsuka M, Konno F, Honda H, Oikawa T, Ishikawa M, Iwase N, Isomae K, Ishii F, Hemmi H, and Sato S (2002) PPA250 [3-(2,4-Difluorophenyl)-6-[2-[4-(1H- imidazol- 1-ylmethyl) phenoxy]ethoxy]-2-phenylpyridine], a novel orally effective inhibitor of the dimerization of inducible nitric-oxide synthase, exhibits an anti-inflammatory effect in animal models of chronic arthritis. J Pharmacol Exp Ther 303:52-57. (Pubitemid 35056449)
21. G-methyl-L-arginine: evidence for heme loss. Biochemistry 33:14784-14791.
22. Paige JS and Jaffrey SR (2007) Pharmacologic manipulation of nitric oxide signaling: targeting NOS dimerization and protein-protein interactions. Curr Top Med Chem 7:97-114. (Pubitemid 46062399)
23. Panda K, Rosenfeld RJ, Ghosh S, Meade AL, Getzoff ED, and Stuehr DJ (2002) Distinct dimer interaction and regulation in nitric-oxide synthase types I, II, and III. J Biol Chem 277:31020-31030. (Pubitemid 34970806)
24. Robertson CA, Green BG, Niedzwiecki L, Harrison RK, and Grant SK (1993) Effect of nitric oxide synthase substrate analog inhibitors on rat liver arginase. Biochem Biophys Res Commun 197:523-528. (Pubitemid 24034601)
25. Sennequier N and Stuehr DJ (1996) Analysis of substrate-induced electronic, catalytic, and structural changes in inducible NO synthase. Biochemistry 35:5883-5892. (Pubitemid 26143682)
26. Sennequier N, Wolan D, and Stuehr DJ (1999) Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J Biol Chem 274:930-938. (Pubitemid 129535254)
27. Siddhanta U, Presta A, Fan B, Wolan D, Rousseau DL, and Stuehr DJ (1998) Domain swapping in inducible nitric-oxide synthase. Electron transfer occurs between flavin and heme groups located on adjacent subunits in the dimer. J Biol Chem 273:18950-18958. (Pubitemid 28366284)
28. Sohn MJ, Hur GM, Byun HS, and Kim WG (2008) Cyclo(dehydrohistidyl-l- tryptophyl) inhibits nitric oxide production by preventing the dimerization of inducible nitric oxide synthase. Biochem Pharmacol 75:923-930. (Pubitemid 351174117)
29. Vallance P and Leiper J (2002) Blocking NO synthesis: how, where and why? Nat Rev Drug Discov 1:939-950. (Pubitemid 37361600)
30. Vos TA, Gouw AS, Klok PA, Havinga R, van Goor H, Huitema S, Roelofsen H, Kuipers F, Jansen PL, and Moshage H (1997) Differential effects of nitric oxide synthase inhibitors on endotoxin-induced liver damage in rats. Gastroenterology 113:1323-1333. (Pubitemid 27418987)
31. Wang W and Malcolm BA (1999) Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange site-directed mutagenesis. Biotechniques 26:680-682. (Pubitemid 129526133)
32. Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, and Sellers EM (2002) Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 30:314-318. (Pubitemid 34175023)